Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-024-03729-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Meng Lv und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shenzhen Hospital of Traditional Chinese Medicine, Shenzhen, China. Hauptthemen laut MEDLINE: Berberine, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cell Cycle Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Sanming Project of Medicine in Shenzhen.
Abstract (Originalsprache)
Berberine (BBR) has been proved to inhibit the malignant progression of non-small cell lung cancer (NSCLC), but the underlying molecular mechanism still needs to be further revealed. NSCLC cells (A549 and H1299) were treated with BBR. CCK8 assay, colony formation assay, flow cytometry, TUNEL staining and transwell assay were used to examine cell proliferation, apoptosis and invasion. The levels of spindle pole body component 25 (SPC25) and NDC80 kinetochore complex component (NUF2) were detected by qRT-PCR or western blot. The interaction between SPC25 and NUF2 was confirmed by Co-IP assay and FISH assay. Xenograft tumors were constructed to assess the anti-tumor role of BBR in vivo. BBR inhibited NSCLC cell growth, invasion and glycolysis. SPC25 was upregulated in NSCLC tissues, and BBR could reduce SPC25 expression in NSCLC cells. SPC25 knockdown repressed NSCLC cell growth, invasion and glycolysis, and its overexpression also reversed the anti-tumor effect of BBR. SPC25 could interact with NUF2, and NUF2 overexpression abolished the inhibitory effect of SPC25 knockdown or BBR on NSCLC cell behaviors. In animal experiments, BBR could suppress NSCLC tumor growth by inhibiting SPC25/NUF2 axis in vivo. BBR mainly played an anti-NSCLC role by targeting SPC25/NUF2 axis, which provided a new idea for NSCLC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Shenzhen Hospital of Traditional Chinese Medicine, Shenzhen, China.
- Department of Hematology and Oncology, Third People's Hospital of Zigong, Zigong, Sichuan, China.
- Department of Cardiopulmonary Rehabilitation and Sleep Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
- Pneumology Department, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
- The First Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, China.
- Department of Respiratory and Critical Care Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, No. 111, Dade Road, Guangzhou, 510120, China. caijx6807@163.com.
Förderung
- Sanming Project of Medicine in Shenzhen
Zitieren
APA
Lv, M., Chen, X., Yang, Q., Huang, C., Lv, Y., Zhang, T., & Cai, J. (2025). Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-03729-w
Vancouver
Lv M, Chen X, Yang Q, Huang C, Lv Y, Zhang T, et al. Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-024-03729-w
BibTeX
@article{Lv2025,
author = {Lv, Meng and Chen, Xiangrui and Yang, Qiting and Huang, Chushuan and Lv, Yongbiao and Zhang, Tian and Cai, Junxiang},
title = {Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-024-03729-w}
}
EUVIMED